credentis ag has met the high quality standards set by Health Canada without any non- conformities. During this intensive inspection, the quality management system of credentis was successfully inspected. As a result, credentis is now allowed to receive the import licence for Canada and to market its ground-breaking product Curodont™ for the regeneration of defect teeth in Canada.
With this milestone, credentis is able to enter the North American market!
About Curodont™ and Self-Assembling Peptides
Curodont™ is based on the patented “Self-Assembling Peptide”- technology. The technology enables the formation of a three-dimensional matrix in an almost closed environment. The matrix itself acts as a scaffold for tissue regeneration, e.g. the formed matrix enables de-novo formation of Calciumphosphate crystals within an initial carious lesion.
Curodont™, with its main component the self-assembling peptide P11-4, is the first product of credentis that has obtained market approval (CE-label).
Curodont™ provides dentists with a novel technology for in depth regeneration rather than repair of caries and similar tooth decay. Applied to an initial carious lesion, Curodont™ forms a scaffold of small fibres within the lesion. Around these fibres new enamel or dentin can form and grow. Ideally, within several weeks, the lesion will regenerate without the use of the dental drill or a filler material.
About credentis ag
credentis ag has its headquarters in the Technopark Aargau Switzerland, Windisch; the young team was voted #33 of Top Swiss Startups 2011 and was one of the Swiss Venture Leaders 2011.
CEO Dominik Lysek and CTO Michael Hug have expert knowledge in medicinal technology and a strong network in the dental industry. Dr. Werner Berner (member of the board) and Dr. Erich Platzer (chairman of the board), both members of the StartAngels Network, perfectly complement the know-how of the managem
Contact: Dr. Dominik Lysek, CEO, tel +41 56 560 2044; info@credentis.com
